Aarti Drugs Limited (NSE:AARTIDRUGS)
India · Delayed Price · Currency is INR | Market Cap | 34.54B +6.9% |
| Revenue (ttm) | 25.68B +7.6% |
| Net Income | 1.95B +15.9% |
| EPS | 21.36 +15.9% |
| Shares Out | n/a |
| PE Ratio | 17.72 |
| Forward PE | 16.87 |
| Dividend | 2.00 (0.50%) |
| Ex-Dividend Date | Feb 9, 2026 |
| Volume | 214,947 |
| Average Volume | 167,006 |
| Open | 365.90 |
| Previous Close | 365.90 |
| Day's Range | 363.00 - 381.70 |
| 52-Week Range | 318.95 - 564.05 |
| Beta | 0.36 |
| RSI | 53.49 |
| Earnings Date | May 15, 2026 |
About Aarti Drugs
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, ... [Read more]
Financial Performance
In fiscal year 2026, Aarti Drugs's revenue was 25.68 billion, an increase of 7.57% compared to the previous year's 23.87 billion. Earnings were 1.95 billion, an increase of 15.91%.
Financial StatementsNews
Aarti Drugs Transcript: Q4 25/26
Q4 FY 2026 saw strong sequential recovery with revenue up 20% QoQ and EBITDA margin at 13.4%. Backward integration and new facilities drove margin improvement, while exports and regulated markets gained share. FY 2027 targets 13.5%-14% EBITDA margin and 8%-10% volume growth.
Pharma sector stocks fall today, May 18: Alembic Pharma crashes 8.32%, Natco Pharma down 2.48%, Aarti Drugs declines 2.27%
Indian pharmaceutical stocks traded mostly lower on May 18 2026 during the morning session. The BSE Healthcare index declined 0.87% to 46,781.22, in line with the broader market weakness. The…
Aarti Drugs reports Rs 721.1 crore revenue in Q4 FY26 with 6% YoY growth
Aarti Drugs Limited, a diversified pharmaceutical company based in Mumbai, announced its audited financial results for the fourth quarter and financial year ending 31st March 2026. The company reporte...
Aarti Drugs reports comprehensive income of ₹17,169 crore for FY26
Aarti Drugs Limited has announced its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026. The company's total comprehensive income for the year stood…
Pharma sector stocks surge today, April 27: Sun Pharma jumps 6.62%, Aarti Drugs up 3.50%, Alembic Pharma rises 2.86%
Indian pharmaceutical stocks broadly advanced on Monday morning, with the Nifty Pharma Index rising 2.4% to 23,131.5. The S&P BSE Healthcare Index climbed 1.47% to 44,259.96, outperforming the broader...
Aarti Drugs launches 'Saksham Niveshak' campaign to address unpaid dividends
Aarti Drugs has announced the relaunch of the 'Saksham Niveshak' campaign, a 100-day initiative aimed at reaching out to shareholders with unpaid or unclaimed dividends. The campaign, which runs from…
Pharma sector stocks today, March 12: Divi's Laboratories down 1.87%, Abbott India drops 1.51%, Aarti Drugs falls 1.36%
The Indian pharmaceutical sector experienced a decline on March 12, 2026, with most listed stocks trading lower in early morning sessions. The S&P BSE HEALTHCARE Index stood at 43,421.7, down…
Aarti Drugs Ltd (BOM:524348) Q3 2026 Earnings Call Highlights: Strong PAT Growth Amidst ...
Aarti Drugs Ltd (BOM:524348) Q3 2026 Earnings Call Highlights: Strong PAT Growth Amidst Operational Challenges
Q3 2026 Aarti Drugs Ltd Earnings Call Transcript
Q3 2026 Aarti Drugs Ltd Earnings Call Transcript
Aarti Drugs Transcript: Q3 25/26
Revenue and PAT grew strongly YoY, despite margin pressure from weak antibiotic demand and supply chain issues. New facilities and backward integration are ramping up, with significant CapEx planned for oncology and specialty chemicals. Gross margin and EBITDA are expected to improve as utilization increases.
Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92%
The pharma sector displayed mixed performance in early trading on February 4, 2026. While some stocks recorded gains, others faced...
Why are Aarti Drugs shares down over 8% today: Explained
Shares of Aarti Drugs Limited declined sharply by more than 8% in early trade after the company reported its Q3...
Pharma sector stocks down today, jan 29: Dr. Reddy’s Lab drops 2.45%, Zydus falls 1.44%, Aarti Drugs down 1.86%
The Indian pharma sector showed mixed to negative performance on January 29, 2026, as of 10:18 AM IST, amid broader...
Aarti Drugs Ltd (BOM:524348) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Aarti Drugs Ltd (BOM:524348) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Domestic Challenges
Q2 2026 Aarti Drugs Ltd Earnings Call Transcript
Q2 2026 Aarti Drugs Ltd Earnings Call Transcript
Aarti Drugs Earnings Call Transcript: Q2 2026
Revenue and profitability grew strongly year-over-year, driven by robust export demand and margin expansion from backward integration and new capacity ramp-up. Guidance targets high single-digit growth for H2 FY 2026 and margin improvement to 15% by end FY 2027, with continued CapEx and stable leverage.
Aarti Drugs Q2 FY26 results: Net profit rises 29% YoY to Rs 45.2 crore; revenue up 9% to Rs 652.8 crore
Aarti Drugs Limited announced its financial results for the quarter ended September 30, 2025 (Q2 FY26), posting a solid year-on-year...
Aarti Drugs shares jump 2% as new plant begins operations
Aarti Drugs Ltd witnessed a sharp 2% rise in its share price during early trade on September 5, 2025, after the company announced that its new manufacturing facility has started commercial operations....
Aarti Drugs Transcript: Q1 25/26
Revenue grew 6% year-on-year in Q1 FY 2026, with gross margin up 130 bps and EBITDA up 12%. Capacity expansions, backward integration, and new regulatory approvals are set to drive double-digit growth and margin improvement, with 15–16% EBITDA margin targeted by FY 2027.
Aarti Drugs shares rise nearly 2% after strong Q1 results, net profit jumps 63% YoY
Shares of Aarti Drugs Ltd gained nearly 2% on Monday to trade at ₹532 after the company reported robust earnings for the quarter ended June 2025. The pharmaceutical company’s net profit surged 62.7% y...
Aarti Drugs Q1 Results: Revenue up 6.3% YoY to Rs 590 crore, Net Profit up 62.7% YoY
Aarti Drugs Limited on Friday announced its financial results for the quarter ended June 30, 2025 (Q1 FY26), posting a significant rise in profitability supported by improved margins and healthy reven...
Aarti Drugs Transcript: Q4 24/25
Q4 FY25 saw 9% revenue growth and improved margins, driven by strong API export demand and operational efficiencies. FY26 guidance targets double-digit revenue growth and 14-15% EBITDA margin, with new capacity and backward integration supporting expansion.
Aarti Drugs share price jumps 6% as Q4 EBITDA rises 8.9% YoY to Rs 93.4 crore
Aarti Drugs Ltd saw its shares jump 6% after the company reported a robust financial performance for the March quarter of FY25. As of 9:16 AM, the shares were trading 4.89% higher at Rs 367.00. The ph...
Aarti Drugs Q4 results: Revenue up 9.1% YoY to Rs 676.76 crore, Net profit rises 32% YoY
Aarti Drugs Limited reported its financial results for the fourth quarter ended March 31, 2025, showcasing a significant improvement in profitability. The company posted a consolidated net profit of ₹...
Aarti Drugs receives US FDA clearance, removed from Import Alert 66-40
Aarti Drugs Limited announced that it has successfully been removed from the United States Food and Drug Administration (US FDA) Import Alert 66-40, paving the way for the company to resume exports to...